Squamous cell carcinoma in solid-organ transplantation

Dermatology Online Journal

Volumn 8, Issue 2, 2002, Pages 38-59

  Wu, Jashin J ^a   Orengo, Ida F ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; LEUKOCYTE ANTIGEN;

ACTINIC KERATOSIS; CANCER MORTALITY; DIABETES MELLITUS; ENZYME POLYMORPHISM; GENDER; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ONSET AGE; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SKIN CANCER; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; SUNLIGHT; TREATMENT PLANNING; ULTRAVIOLET RADIATION; VIRUS INFECTION; WART VIRUS;

EID: 3242697883     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994;7:99-109.
2. Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, Vandenbroucke JP, Vermeer BJ, Claas FH. HLA-A11 associated resistance to skin cancer in renal-transplant recipients. N Engl J Med 1990;323:1350.
3. Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, Vandenbroucke JP, Vermeer BJ, Claas FH. On a possible protective effect of HLA-A11 against skin cancer and keratotic skin lesions in renal transplant recipients. J Invest Dermatol 1991;97:269-72.
4. McGregor JM, Reddi G, MacDonald D, Vaughan RW, Welsh KI. HLA-A11 in renal allograft recipients with skin cancer. J Invest Dermatol 1992;98:261-2.
5. Glover MT, Bodmer J, Bodmer W, Kennedy LJ, Brown J, Navarrete C, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993;29A:520-4.
6. Bouwes Bavinck JN, Robertson I, Wainwright RW, Green A. Excessive numbers of skin cancers and pre-malignant skin lesions in an Australian heart transplant recipient. Br Heart J 1995;74:468-70.
7. Dyall-Smith D, Ross JB. Cutaneous malignancies in renal transplant recipients from Nova Scotia, Canada. Australas J Dermatol 1995;36:79-82.
8. Bouwes Bavinck JN. Epidemiological aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Hum Exp Toxicol 1995;14:98.
9. Bouwes Bavinck JN, Claas FH, Hardie DR, Green A, Vermeer BJ, Hardie IR. Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. J Invest Dermatol 1997;108:708-11.
10. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, Vandenbroucke JP, Schreuder GM, Thorogood J, et al. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991;325:843-8.
11. Czarnecki D, Watkins F, Leahy S, Dyall-Smith D, Levis A, Nicholson I, et al. Skin cancers and HLA frequencies in renal transplant recipients. Dermatology 1992;185:9-11.
12. Marshall SE, Bordea C, Haldar NA, Mullighan CG, Wojnarowska F, Morris PJ, et al. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney Int 2000;58:2186-93.
13. Ramsay HM, Harden PN, Reece S, Smith AG, Jones PW, Strange RC, et al. Polymorphisms in glutathione S-transferase are associated with altered risk on nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001;117:251-5.
14. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than RB. Mol Pathol 2001;54:165-9.
15. Shuttleworth D, Marks R, Griffin PJA, Salaman JR. Epidermal dysplasia cyclosporine therapy in renal transplant patients: a comparison with azathioprine. Br J Dermatol 1989;120:551-4.
16. Douds AC, Mellotte GJ, Morgan SH. Fatal Merkel-cell tumour (cutaneous neuroendocrine carcinoma) complicating renal transplantation. Nephrol Dial Transplant 1995;10:2346-8.
17. Mouquet C, Benalia H, Ourahma S, Barrou B, Bitker MO, Luciani J, et al. Incidence of non-cutaneous malignancies in kidney transplant recipients: a 20-year follow-up. Transplant Proc 1995;27:1764.
18. Hiesse C, Larue JR, Kriaa P, Blanchet P, Bellamy J, Benoit G, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995;27:2450-1.
19. Zuniga-A V, Alvarez-A L, Diliz-P H. Neoplasia in renal transplantation. Transplant Proc 1996;28:3332.
20. Behrend M, Kolditz M, Kliem V, Oldhafer KJ, Brunkhorst R, Frei U, et al. Malignancies in patients under long-term immunosuppression after kidney transplantation. Transplant Proc 1997;29:834-5.
21. Hiesse C, Rieu P, Kriaa F, Larue JR, Goupy C, Neyrat N, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997;29:831-3.
22. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997;349:398.
23. Sheil AG, Hall BM, Tiller DJ. Cyclosporine A versus standard therapy for cadaveric donor renal transplantation. Transplant Proc 1984;16:992-4.
24. Penn I. Cancers following cyclosporine therapy. Transplantation 1987;43:32-5.
25. Penn I, Brunson ME. Cancers after cyclosporine therapy. Transplant Proc 1988;20:885-92.
26. Barr BBB, McLaren K, Smith IW, Bunney MH, Smith IW, Blessing K, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989;1:124-9.
27. Blohme I, Larkoe O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol Suppl (Stockh) 1990;70:491-4.
28. Espana A, Redondo P, Fernandez AL, Zabala M, Herreros J, Llorens R, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995;32:458-65.
29. Marks R, Kolley D, Lectas S. The risk of childhood exposure to sunlight in the development of solar keratoses and non-melanotic skin cancer. Med J Aust 1990;152:62-6.
30. Bunney MH, Benton EC, Barr BB, Smith IW, Anderton JL, Hunter JA. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990;5:379-82.
31. Gruber SA, Skjei KL, Sothern RB, Robison L, Tzardis P, Moss A, et al. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transplant Proc 1991;23:1104-5.
32. Blohme I, Larkoe O. No difference in skin cancer incidence with or without cyclosporine- a five-year perspective. Transplant Proc 1992;24:313.
33. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow up study. Transplantation 1996;61:715-21.
34. Jensen P, Clausen OPF, Geiran O, Simonsen S, Relbo A, Hansen S, et al. Cutaneous complications in heart transplant recipicients in Norwar 1983-1993. Acta Derm Venereol Suppl (Stockh) 1995;75:400-3.
35. Bouwes Bavinck JN, Claas FH. The role of HLA molecules in the development of skin cancer. Hum Immunol 1994;41:173-9.
36. Streilein JW. Immunogenetic factors in skin cancer. N Engl J Med 1991;325:884-6.
37. Bergfelt L, Larkoe O, Blohme I. Skin disease in immunosuppressed patients in relation to epidermal Langerhans' cells. Acta Derm Venereol Suppl (Stockh) 1993;73:330-4.
38. Penn I. Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996;28:876-8.
39. Taylor AEM, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol Suppl (Stockh) 1992;72:115-9.
40. Leigh IM, Glover MT. Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995;139:69-86.
41. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolities, I: 6-mercaptopurine. Photochem Photobiol 1986;43:247-55.
42. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolities, II: azathioprine and nitroimidazole metabolites. Photochem Photobiol 1986;43:257-62.
43. Euvrard S, Chardonnet Y, Pouteil-Noble CP, Kanitakis J, Thivolet J, Touraine JL. Skin malignancies and human papillomaviruses in renal transplant recipients. Transplant Proc 1993;25:1392-3.
44. Stark LA, Arends MJ, McLaren KM, Benton EC, Shahidullah H, Hunter JA, et al. Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumor promotion. Br J Cancer 1994;69:222-9.
45. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, zur Hausen H, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994;54:4610-3.
46. Shamanin V, zur Hausen H, Lavergne D, Proby CM, Leigh IM, Neumann C, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996;88:802-11.
47. Hoepfl R, Bens G, Wieland U, Petter A, Zelger B, Fritsch P, et al. Human papillomavirus DNA in non-melanoma skin cancers of a renal transplant recipient: detection of a new sequence related to epidermodysplasia verruciformis associated types. J Invest Dermatol 1997;108:53-6.
48. Pierceall WE, Goldberg LH, Anathaswamy HN. Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers. J Invest Dermatol 1991;97:880-4.
49. Blessing K, McLaren KM, Benton EC, Barr BB, Bunney MH, Smith IW, et al. Histopathology of skin lesions in renal allograft recipients- an assessment of viral features and dysplasia. Histopathology 1989;14:129-39.
50. Bouwes Bavinck JN, Gissman L, Claas FHJ, Van der Woude FJ, Persijn GG, Ter Schegget J, et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993;151:1579-86.
51. Pelisson I, Soler C, Chardonnet Y, Euvrard S, Schmitt D. A possible role for human papillomaviruses and c-myc, c-Ha-ras, and p53 gene alterations in malignant cutaneous lesions from renal transplant recipients. Cancer Detect Prev 1996;20:20-30.
52. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-97.
53. Weissenborn SJ, Hopfl R, Weber F, Smola H, Pfister HJ, Fuchs PG. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol 1999;113:122-6.
54. Boxman ILA, Berkhout RJM, Mulder LHC, Wolkers MC, Bouwes Bavinck JN, Vermeer BJ, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997;108:712-715.
55. Bouwes Bavinck JN, De Boer A, Vermeer BJ, Hartevelt MM, van der Woude FJ, Claas FH, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-9.
56. Kelley GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987;117:429-40.
57. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
58. Noonan FP, De Fabo EC. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunol Today 1992;13:250-4.
59. Ferrandiz C, Fuente MJ, Fernandez-Figueras MT, Bielsa I, Just M. p53 immunohistochemical expression in early posttransplant-associated malignant and premalignant cutaneous lesions. Dermatol Surg 1999;25:97-101.
60. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses? Diagn Mol Pathol 2001;10:190-9.
61. Black HS, deGruijl FR, Forbes PD, Cleaver JE, Ananthaswamy HN, deFabo EC, et al. Photocarcinogenesis: an overview. J Photochem Photobiol 1997;40:29-47.
62. Cruz PD Jr, Bergstresser PR. Ultraviolet radiation, Langerhans' cells, and skin cancer: conspiracy and failure. Arch Dermatol 1989;125:975-9.
63. Kripke ML. Immunological responsiveness induced by ultraviolet radiation. Immunol Rev 1984;80:87-102.
64. Pamphilon KH, Alnaqdy AA, Wallington TB. Immunomodulation by ultraviolet light: clinical studies and biological effects. Immunol Today 1991;12:119-23.
65. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986;122:1288-93.
66. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JPA. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6.
67. Hartevelt MM, Bavinck JNB, Kootte AMM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9.
68. Sheil AG, Disney APS, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant Proc 1992;24:1946-7.
69. Penn I. Skin disorders in organ transplant recipients. Arch Dermatol 1997;133:221-3.
70. Bourke JF, Mellott GJ, Young G, Donohoe J, Carmody M, Keogh JA. Skin cancer in an Irish renal transplant population. Ir J Med Sci 1992;161:116-7.
71. Sheil AGR. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992;24:1275-9.
72. Roeger LS, Sheil AGR, Disney APS, Mathew TH, Amiss N. Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients. Clin Transpl 1992;6:202-11.
73. Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994;8:388-95.
74. Liddington M, Richardson AJ, Higgins RM, Endre ZH, Venning VA, Murie JA, et al. Skin cancer in renal transplant recipients. Br J Surg 1989;76:1002-5.
75. Euvrard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine JL, Faure M, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33:222-9.
76. Naldi L, Fortina AB, Lovati S, Barba A, Gotti E, Tessari G, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000;70:1479-84.
77. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000;36:167-76.
78. Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993;72:2186-9.
79. Orengo I, Brown T, Rosen T. Cutaneous neoplasia in organ transplant recipients. Curr Probl Dermatol 1999;11:121-60.
80. Euvrard S, Chardonnet Y, Pouteil-Noble C. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993;72:2198-206.
81. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979;2:1461-6.
82. Lanza RP, Cooper DK, Cassidy MJ, Barnard CN. Malignant neoplasms occurring after cardiac transplantation. JAMA 1983;249:1746-8.
83. Jensen P, Moller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000;42:307.
84. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86.
85. Bordea C, Cortina-Borja M, Wojnarowska F, Morris PJ. Distribution of upper limb skin cancers in relation to arteriovenous fistula side in renal transplant recipients. Transplantation 2001;71:143-5.
86. Wong WWS, Bain VG. Update in liver transplantation. Can Fam Physician 1999;45:1241-49.
87. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000;6:253-62.
88. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, et al. De novo malignancy following liver transplantation: A single-center study. Transplant Proc 1993;25:1397-1399.
89. Frezza EE, Fung JJ, Van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997;44:1172-1181.
90. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancy after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80:1141-50.
91. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66:1193-1200.
92. Hartevelt MM, Bouwes Bavinck JN, Kootte AMM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9.
93. Butt A, Roberts DL. Renal transplant recipients and protection from sun: need for education. Lancet 1997;349:179-80.
94. Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J Am Acad Dermatol 1999;40:697-701.
95. Barba A, Tessari G, Boschiero L, Chieregato G. Renal transplantation and skin diseases: review of the literature and results of a five-year follow-up of 285 patients. Nephron 1996;73:131-6.
96. Blohme I, Larkoe O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation 1984;37:165-7.
97. Euvrard S, Kanitakis J, Pouteil-Noble C, Disant F, Villaine JF, Claudy A, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995;27:1767-8.
98. Leigh IM, Glover MT. Cutaneous warts and tumours in immunosuppressed patients. J R Soc Med 1995;88:61-2.
99. Yuan Z, Davis A, MacDonald K, Bailey RR. Use of acitretin for the skin complications in renal transplant recipients. N Z Med J 1995;108:255-6.
100. Vandeghinste N, De Bersaques J, Geerts ML, Kint A. Acitretin as cancer chemoprophylaxis in a renal transplant recipient. Dermatology 1992;185:307-8.
101. Bouwes Bavinck JN, Tieben LM, Van Der Woude FK, Tegzess AM, Hermans J, ter Schegget J, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-8.
102. Shuttleworth D, Marks R, Griffin PJA, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988;257:717-24.
103. McKerrow KJ, Mackie RM, Lesko MJ, Pearson C. The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol 1988;119:313-20.
104. Kelly JW, Sabto J, Gurr FW, Bruce F. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991;2:1407.
105. Strumia R, Perini L, Tarroni G, Fiocchi O, Gilli P. Skin lesions in kidney transplant recipients. Nephron 1992;62:137-41.
106. Rook AH, Jaworsky C, Nguyen T, Grossman RA, Wolfe JT, Witmer WK, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant lesions in renal transplant recipients. Transplantation 1995;59:714-9.
107. Bellman BA, Eaglstein WH, Miller J. Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation 1996;61:173.
108. Euvrard S, Verschoore M, Touraine JL, Dureau G, Cochat P, Czernielewski J, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992;340:48-9.
109. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44:462-70.
110. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon inducing imidazoquinolinamine. Cancer Res 1992;52:3528-33.
111. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. A randomised, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.